Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Dec. 10, 2024
Background
Programmed
death-ligand
1
(PD-L1)
expression
is
abundant
not
only
in
malignant
cells
but
also
infiltrating
within
the
tumor
microenvironment
(TME)
of
hepatocellular
carcinoma
(HCC).
This
study
explored
association
between
PD-L1
TME
and
outcomes
HCC
patients
treated
with
atezolizumab
plus
bevacizumab
(AB),
emphasizing
implications
both
tumor-infiltrating
cells.
Methods
included
72
who
underwent
percutaneous
core
needle
liver
biopsy
before
AB
treatment
September
2020
December
2023.
on
tissues
was
assessed
using
combined
positive
score
(CPS)
cutoff
values
10,
utilizing
antibody
clone
22C3
(Dako).
Results
The
distribution
CPS
24
<1,
33
1–10,
15
≥10.
Significant
differences
overall
survival
(OS)
were
observed
across
three
groups,
≥10
showing
highest
rates
(p
=
0.010).
Patients
had
better
OS
than
those
<10
(median
14.8
vs.
8.3
months,
P
0.046),
≥1
<1
(P
0.021).
For
progression-free
(mPFS),
group
median
PFS
11.0
months
among
groups
0.044).
Objective
response
(ORR)
higher
1-10
(53.3%,
27.3%,
16.7%,
respectively;
.047).
Multivariate
analysis
identified
that
associated
favorable
regarding
(hazard
ratio
[HR]
0.283,
.027
HR
0.303,
.006,
respectively).
Conclusions
Combined
can
be
a
promising
biomarker
for
prognosis
AB.
Cancer Reports,
Journal Year:
2024,
Volume and Issue:
7(4)
Published: April 1, 2024
Abstract
Aims
The
aim
of
the
present
study
was
to
elucidate
detailed
parameters
for
prediction
prognosis
patients
with
unresectable
hepatocellular
carcinoma
(uHCC)
receiving
atezolizumab
plus
bevacizumab
(Atez/Bev)
treatment.
Methods
A
total
719
(males
577,
median
age
74
years)
treated
Atez/Bev
between
September
2020
and
January
2023
were
enrolled.
Factors
related
overall
survival
(OS)
extracted
a
prognostic
scoring
system
based
on
hazard
ratio
(HR)
created.
OS
progression‐free
(PFS)
retrospectively
examined,
ability
newly
developed
compared
CRAFITY
score
using
concordance
index
(c‐index)
Akaike
information
criterion
(AIC)
results.
Results
Cox‐hazards
multivariate
analysis
showed
BCLC
classification
C/D
(HR
1.4;
1
point),
AFP
≥100
ng/mL
mALBI
2a
1.7;
2b/3
2.8;
2
points),
DCP
mAU/mL
1.6;
point)
as
significant
factors.
assigned
points
added
used
develop
IMmunotherapy
AFP,
staging,
mALBI,
evaluation
(IMABALI‐De)
system.
For
IMABALI‐De
scores
0,
1,
2,
3,
4,
5,
not
applicable
(NA),
NA,
26.11,
18.79,
14.07,
8.32
months,
respectively
(
p
<
.001;
AIC
2788.67,
c‐index
0.699),
while
20.29,
11.32
2864.54,
0.606).
PFS
periods
those
21.75,
12.89,
9.18,
8.0,
5.0,
3.75
5203.32,
0.623)
10.32,
7.68,
3.57
5246.61,
0.574).
As
score,
had
better
results
both
PFS.
Conclusion
indicated
that
proposed
may
be
favorable
predicting
uHCC
therapy.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 4, 2025
Abstract
Purpose
Hepatocellular
carcinoma
(HCC)
is
the
most
common
form
of
liver
cancer
with
a
bad
prognosis
in
case
advanced
HCC,
only
eligible
for
palliative
systemic
therapies.
After
decade
exclusive
sorafenib
monotherapy,
response
rate
<10%,
advent
immunotherapies
represents
revolution
HCC.
The
combination
atezolizumab/bevacizumab
recommended
as
first-line
treatment,
around
30%.
However,
there
are
currently
no
predictive
factors
to
these
treatment
options.
Experimental
Design
We
profiled,
by
high-resolution
mass
spectrometry-based
proteomics
combined
machine
learning
analysis,
selected
cohort
fixed
biopsies
grouped
subjects
according
their
objective
treatments,
corresponded
tumor
regression
vs
progression
at
4
months
after
treatment.
Results
generated
proteome
database
50
HCC
samples.
compared
relative
protein
abundance
between
tumoral
and
non-tumoral
tissues
from
patients
treated.
clear
distinction
two
groups
each
based
on
deregulation
141
or
87
respectively.
These
specific
proteomic
signatures
were
sufficient
predict
revealed
biological
pathways
involved
treatment’s
resistance.
Particularly,
we
validated
shift
cell
metabolism
an
immunosuppressive
environment
resistance
combination.
Conclusions
performed
in-depth
analysis
quantitative
data
giving
ability
optimize
patient
management.
International Journal of Nanomedicine,
Journal Year:
2025,
Volume and Issue:
Volume 20, P. 2623 - 2643
Published: March 1, 2025
In
recent
years,
nanobiotechnology,
widely
used
in
hepatoma,
holds
great
promise
for
improving
targeted
hepatocarcinoma
therapy.
On
account
of
the
unique
properties
low
toxicity,
good
tolerance,
biocompatibility,
and
biodegradability
new
nanomaterials,
a
drug
delivery
system
(TDDS)
has
been
constructed,
which
can
boost
therapeutic
effect
hepatoma-targeted
drugs,
reduce
minimize
off
target
reactions
by
enhancing
permeability
retention
(EPR)
active
targeting,
thus
existing
liver
cancer
therapy
strategies.
Different
nanoparticles
have
their
own
advantages
disadvantages.
They
be
loaded
with
multiple
drugs
on
same
nanoparticle
also
surface
modified
each
other
to
achieve
synergistic
anti-tumor
effects.
This
essay
provides
comprehensive
overview
current
status
hepatocarcinoma,
nanoparticles'
structure,
disadvantages
nanoparticle,
application
progress
cancer.
We
hope
provide
basis
future
clinical
hepatoma
using
nanotechnology.
Clinical Nuclear Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 21, 2025
Background:
This
study
aimed
to
assess
prognostic
significance
of
FDG
PET/CT
parameters
in
predicting
progression-free
survival
(PFS)
and
overall
(OS)
patients
with
hepatocellular
carcinoma
(HCC)
treated
atezolizumab
plus
bevacizumab
therapy.
Patients
Methods:
We
retrospectively
enrolled
78
HCC
who
underwent
before
therapy
identified
intrahepatic
target
tumor
lesions
on
pretreatment
imaging
studies.
From
images,
we
measured
SUVmax,
tumor-to-normal
liver
uptake
ratio,
metabolic
volume,
total
lesion
glycolysis
(TLG)
for
lesions,
as
well
SUVmax
extrahepatic
metastatic
(extrahepatic
SUVmax).
Results:
In
comparisons
parameters,
progressive
disease
demonstrated
significantly
higher
TLG
values
than
those
achieving
complete
or
partial
response
(
P
<
0.05).
the
multivariate
analysis,
independently
predicted
both
PFS
=
0.019)
OS
0.003).
Metabolic
volume
was
associated
alone
0.010),
only
0.045).
high
experienced
poorer
low
Conclusions:
treatment
served
an
independent
factor
OS.
could
be
a
potential
biomarker
clinical
outcomes
receiving
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: Feb. 28, 2024
Atezolizumab+bevacizumab
(AB)
and
lenvatinib
have
been
proposed
as
first-line
treatment
options
for
patients
with
advanced
hepatocellular
carcinoma
(HCC),
but
comparative
efficacy
associated
factors
are
controversial.
This
real-world
multicenter
study
analysed
HCC
who
received
AB
(n=169)
or
(n=177).
First,
1:1
propensity
score
matching
(PSM)
was
performed,
resulting
in
141
both
the
groups.
After
PSM,
overall
survival
(OS)
better
group
than
[hazard
ratio
(HR)=0.642,
P=0.009],
progression-free
(PFS)
did
not
vary
between
two
groups
(HR=0.817,
P=0.132).
Objective
response
rate
(ORR)
also
similar
(34.8%
vs.
30.8%,
P=0.581).
In
a
subgroup
of
objective
responses
(OR,
n=78),
OS
(HR=0.364,
P=0.012)
PFS
(HR=0.536,
P=0.019)
were
(n=41)
(n=37).
Time-to-progression
from
time
OR
(HR=0.465,
P=0.012).
Importantly,
residual
liver
function
significant
factor
related
to
treatments.
Child-Pugh
following
cessation
respective
treatments
(n=105)
(n=126)
(median
6
versus
7,
P=0.008),
proportion
salvage
higher
(52.4%
38.9%,
P=0.047).
When
we
adjusted
treatment,
there
no
difference
Our
suggests
that
subsequent
major
determinants
clinical
outcomes
treated
lenvatinib;
these
should
be
considered
future
studies.
Oncology Letters,
Journal Year:
2024,
Volume and Issue:
28(2)
Published: June 21, 2024
Atezolizumab/bevacizumab
is
the
first
line
of
treatment
for
unresectable
hepatocellular
carcinoma
(HCC),
combining
immune
checkpoint
inhibitor
and
anti‑VEGF
monoclonal
antibodies.
Hepatic
arterial
infusion
chemotherapy
(HAIC)
administered
when
above‑described
combination
fails
to
confer
sufficient
clinical
benefit.
The
present
study
aimed
explore
association
between
tumor
programmed
cell
death‑ligand
1
(PD‑L1)
positivity
HAIC
response.
A
total
40
patients
with
HCC
who
had
undergone
available
biopsy
samples
obtained
January
2020
May
2023
were
retrospectively
enrolled.
Tumor
response,
progression‑free
survival
(PFS),
disease
control
rate
(DCR)
overall
(OS)
evaluated.
PD‑L1
expression
in
was
assessed
using
a
combined
score.
response
rates
HAIC‑treated
advanced
after
failure
atezolizumab/bevacizumab
therapy
recorded.
OS
(P=0.9717)
PFS
(P=0.4194)
did
not
differ
without
positivity.
objective
(P=0.7830)
DCR
(P=0.7020)
also
based
on
status.
In
conclusion,
current
findings
highlight
consistent
efficacy
HAIC,
regardless
Liver Cancer,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 13
Published: Sept. 2, 2024
Introduction:
Variability
in
response
to
atezolizumab
plus
bevacizumab
(AB)
treatment
of
hepatocellular
carcinoma
(HCC)
underscores
the
critical
need
for
development
effective
biomarkers.
We
sought
identify
peripheral
blood
biomarkers
reflecting
AB
treatment.
Methods:
analyzed
dynamic
changes
mononuclear
cells
from
a
prospective,
multicenter
cohort
65
patients
with
HCC,
using
flow
cytometry
evaluate
T-cell
population
before
and
3
weeks
after
first
Results:
found
unique
CD8+
T
terms
both
frequency
phenotype,
contrast
CD4+
regulatory
cells.
Notably,
showed
significant
expression
Ki-67
immunoreceptors
Ig
ITIM
domains
(TIGIT).
These
distinct
responses
were
observed
particularly
programmed
cell
death
receptor-1
(PD-1)+
subpopulation
Interestingly,
baseline
differentiation
status
PD-1+CD8+
cells,
central
memory
subset,
correlated
positively
greater
proliferation
(higher
expression)
Moreover,
effector
expressing
CD45RA
negatively
increase
TIGIT+/PD-1+CD8+
The
TIGIT+/CD8+
was
associated
immune-related
adverse
events,
whereas
Ki-67+/PD-1+CD8+
better
objective
rate.
Importantly,
shifts
significantly
predicted
progression-free
survival
overall
survival,
as
confirmed
by
multivariate
analysis.
Conclusion:
findings
highlight
potential
an
on-treatment
prognostic
biomarker.
Our
study
value
profiling
noninvasive
practical
method
predicting
clinical
outcomes
HCC.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: Dec. 12, 2024
Background
There
is
no
established
second-line
treatment
for
hepatocellular
carcinoma
(HCC)
following
atezolizumab-bevacizumab
(ate-beva)
failure.
This
study
assessed
the
efficacy
of
hepatic
arterial
infusion
chemotherapy
(HAIC)
as
a
salvage
therapy
by
comparing
survival
outcomes
and
responses
between
HAIC
first-line
option
after
ate-beva
Materials
Methods
We
retrospectively
analyzed
100
patients
with
advanced
HCC
treated
March
2022
July
2024.
Patients
were
categorized
into
two
groups:
those
who
received
initial
(first-line
group)
failure
(post-ate-beva
group).
Survival
Kaplan-Meier
curves
log-rank
tests,
factors
associated
identified
through
Cox
regression
analysis.
Results
The
post-ate-beva
group
exhibited
longer
overall
(OS)
(median
OS
12.4
months)
compared
to
6.8
(p
=
0.073).
Progression-free
(PFS)
was
significantly
superior
in
PFS
8.2
3.1
0.018).
objective
response
rate
also
notably
higher
than
(35.3%
vs.
18.1%,
p
0.031).
In
multivariate
analysis,
failure,
HAIC,
favorable
both
0.014)
0.006).
Conclusion
observed
suggest
that
may
be
an
effective
However,
due
retrospective
nature
small
sample
size
study,
further
prospective
studies
larger
patient
populations
are
needed
strengthen
evidence.
American Journal of Clinical Oncology,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Dec. 4, 2023
Objectives:
In
randomized
clinical
trials
in
patients
with
hepatocellular
cancer
(HCC),
combination
therapy
atezolizumab
and
bevacizumab
(Atezo-Bev)
prolonged
survival,
these
treatments
have
become
the
standard
first-line
for
advanced
HCC.
However,
may
not
reflect
real-life
practice
due
to
treatment
selection
criteria.
Thus,
our
aim
was
understand
predictors
of
HCC
outcomes
a
real-world,
multicenter
setting.
Methods:
A
retrospective
review
all
18
years
age
or
older
treated
primary
liver
between
February
2020
August
2022
conducted
assess
relationship
overall
survival
biochemical
variables
before
during
treatment.
Univariate
multivariate
Cox
regression
analyses
were
performed
identify
following
Results:
One
hundred
eleven
eligible
unresectable
received
Atezo-Bev
over
consecutive
30-month
period.
identified
several
significant
(
P
<0.05)
including
pretreatment
albumin
(hazard
ratios
[HR]:
0.2;
CI:
0.1-0.4),
total
bilirubin
(HR:
1.3;
1.2-1.5),
international
normalized
ratio
5.6;
2.5-12.5).
analyses,
significantly
associated
as
mortality,
<3.5
mg/dL
had
lower
than
those
≥3.5
(153
vs.
522
d,
<0.0001).
Conclusions:
Pretreatment
hypoalbuminemia,
high
bilirubin,
tests
indicative
hepatic
renal
dysfunction
can
independently
predict
short-term
mortality
receiving
Atezo-Bev.
